Arcutis Biotherapeutics Inc (ARQT)
9.93
-0.54
(-5.16%)
USD |
NASDAQ |
Nov 14, 16:00
9.925
0.00 (0.00%)
After-Hours: 20:00
Arcutis Biotherapeutics Research and Development Expense (Quarterly): 19.50M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 19.50M |
| June 30, 2024 | 19.30M |
| March 31, 2024 | 23.14M |
| December 31, 2023 | 23.78M |
| September 30, 2023 | 26.24M |
| June 30, 2023 | 25.22M |
| March 31, 2023 | 35.34M |
| December 31, 2022 | 33.88M |
| September 30, 2022 | 69.73M |
| June 30, 2022 | 38.20M |
| March 31, 2022 | 40.62M |
| December 31, 2021 | 52.56M |
| Date | Value |
|---|---|
| September 30, 2021 | 40.60M |
| June 30, 2021 | 30.76M |
| March 31, 2021 | 21.63M |
| December 31, 2020 | 27.37M |
| September 30, 2020 | 32.74M |
| June 30, 2020 | 30.01M |
| March 31, 2020 | 25.18M |
| December 31, 2019 | 10.76M |
| September 30, 2019 | 12.35M |
| June 30, 2019 | 7.214M |
| March 31, 2019 | 6.203M |
| December 31, 2018 | 5.347M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.76M
Minimum
Dec 2019
69.73M
Maximum
Sep 2022
31.33M
Average
28.69M
Median
Research and Development Expense (Quarterly) Benchmarks
| Mirum Pharmaceuticals Inc | 32.67M |
| Biogen Inc | 542.70M |
| Vertex Pharmaceuticals Inc | 875.90M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |